The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
Open accessAbstract
Triple negative breast cancer (TNBC) represents the 15-20% of all breast cancers (BC) and is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a single disease, but it is rather an umbrella for different ontology-profiles such as basal like 1 and 2, mesenchymal, and the luminal androgen receptor (LAR). The LAR subtype is characterized by the expression of the Androgen Receptor (AR) and its downstream effects. Notwithstanding the role of the AR in several signaling pathways, its impact on a biological and clinical standpoint is still controversial. The LAR subtype has been associated with better prognosis, less chemotherapy responsiveness and lower pathologic complete response after neoadjuvant treatment. Clinical evidence suggests a role for anti-androgen therapies such as bicalutamide, enzalutamide and abiraterone, offering an interesting chemo-free alternative for chemo-unresponsive patients, and therefore potentially shifting current treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
Breast cancer intrinsic subtype classification, clinical use and future trends.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015) · Europe PMC (PubMed Central) · Cited by 921
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208429 · Cited by 808
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., & Bhargava, R. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.159 · Cited by 401
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Graham, T. R., Zhau, H. E., Odero-Marah, V. A., Osunkoya, A. O., Kimbro, K. S., Tighiouart, M., Liu, T., Simons, J. W., & O'Regan, R. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2559 · Cited by 384
Expression of androgen receptors in primary breast cancer
Park, S., Koo, J., Park, H. S., Kim, J.-H., Choi, S.-Y., Lee, J. H., Park, B.-W., & Lee, K. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp510 · Cited by 343
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A. M., Andreetta, C., Mansutti, M., Pisa, F. E., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0002 · Cited by 295
Self-citationBonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Barton, V. N., D'Amato, N. C., Gordon, M. A., Lind, H. T., Spoelstra, N. S., Babbs, B. L., Heinz, R. E., Elias, A., Jedlicka, P., Jacobsen, B. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0926 · Cited by 239
Liu, Y.-R., Jiang, Y.-Z., Xu, X.-E., Yu, K.-D., Jin, X., Hu, X., Zuo, W.-J., Hao, S., Wu, J., Liu, G.-Y., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0690-8 · Cited by 226
Pattern of metastasis and outcome in patients with breast cancer
Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A. M., Fasola, G., & Puglisi, F. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9697-2 · Cited by 218
Self-citationReprogramming the immunological microenvironment through radiation and targeting Axl
Aguilera, T. A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M. S., Hui, A. B.-Y., Stehr, H., von Eyben, R., Jiang, D., Ellies, L. G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13898 · Cited by 194
WNT7a induces E-cadherin in lung cancer cells
Ohira, T., Gemmill, R. M., Ferguson, K., Kusy, S., Roche, J., Brambilla, E., Zeng, C., Baron, A., Bemis, L., Erickson, P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734137100 · Cited by 182
He, J., Peng, R., Yuan, Z., Wang, S., Peng, J., Lin, G., Jiang, X., & Qin, T. (2012) · Medical Oncology · doi:10.1007/s12032-011-9832-0 · Cited by 170
Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., Gianni, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1003 · Cited by 164
Naderi, A., & Hughes-Davies, L. (2008) · Neoplasia · doi:10.1593/neo.08274 · Cited by 162
Choi, J. E., Kang, S. H., Lee, S. J., & Bae, Y. K. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3984-z · Cited by 153
Molecular Classification of Triple-Negative Breast Cancer
Ahn, S. G., Kim, S. J., Kim, C., & Jeong, J. (2016) · Journal of Breast Cancer · doi:10.4048/jbc.2016.19.3.223 · Cited by 146
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease
Singh, M., Spoelstra, N. S., Jean, A., Howe, E. N., Torkko, K. C., Clark, H. R., Darling, D. S., Shroyer, K. R., Horwitz, K. B., Broaddus, R. R., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.82 · Cited by 138
Complexities of androgen receptor signalling in breast cancer
McNamara, K. M., Moore, N. L. T., Hickey, T. E., Sasano, H., & Tilley, W. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0243 · Cited by 135
Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
Wang, C., Pan, B., Zhu, H., Zhou, Y., Mao, F., Lin, Y., Xu, Q., & Sun, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10208 · Cited by 132
Barton, V. N., D’Amato, N. C., Gordon, M. A., Christenson, J. L., ELIAS, A. D., & Richer, J. K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0232-3 · Cited by 129
Qu, Q., Mao, Y., Fei, X., & Shen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082650 · Cited by 127
Rahim, B. G., & O'Regan, R. M. (2017) · Cancers · doi:10.3390/cancers9030021 · Cited by 123
The Role of the Androgen Receptor in Triple-Negative Breast Cancer
Shah, P. D., Gucalp, A., & Traina, T. A. (2013) · Women s Health · doi:10.2217/whe.13.33 · Cited by 121
Sutton, L. M., Cao, D., Sarode, V. R., Molberg, K. H., Torgbe, K., Haley, B., & Peng, Y. S. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcp8avf8fdptzlh · Cited by 107
Androgen receptor signaling pathways as a target for breast cancer treatment
Pietri, E., Conteduca, V., Andreis, D., Massa, I., Melegari, E., Sarti, S., Cecconetto, L., Schirone, A., Bravaccini, S., Serra, P., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0190 · Cited by 102
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers
Wang, Y., Romigh, T., He, X., Tan, M.-H., Orloff, M., Silverman, R. H., Heston, W. D. W., & Eng, C. (2011) · Oncogene · doi:10.1038/onc.2011.144 · Cited by 98
Targeting the androgen receptor in triple-negative breast cancer
Gucalp, A., & Traina, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.004 · Cited by 93
Gasparini, P., Fassan, M., Cascione, L., Güler, G., Balcı, S., Irkkan, Ç., Paisie, C. A., Lovat, F., Morris, Q., Zhang, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088525 · Cited by 92
Asano, Y., Kashiwagi, S., Onoda, N., Kurata, K., Morisaki, T., Noda, S., Takashima, T., Ohsawa, M., Kitagawa, S., & Hirakawa, K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.434 · Cited by 84
Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells
Graham, T. R., Yacoub, R., Taliaferro-Smith, L. D., Osunkoya, A. O., Odero-Marah, V., Liu, T., Kimbro, K. S., Sharma, D., & O'Regan, R. M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0623-7 · Cited by 83
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
Basile, D., Cinausero, M., Iacono, D., Pelizzari, G., Bonotto, M., Vitale, M. G., Gerratana, L., & Puglisi, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.006 · Cited by 83
Self-citationExpression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
Asano, Y., Kashiwagi, S., Goto, W., Tanaka, S., Morisaki, T., Takashima, T., Noda, S., Onoda, N., Ohsawa, M., Hirakawa, K., et al. (2017) · Cancers · doi:10.3390/cancers9010004 · Cited by 81
Darb‐Esfahani, S., Denkert, C., Stenzinger, A., Salat, C., Sinn, B. V., Schem, C., Endris, V., Klare, P., Schmitt, W., Blohmer, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11891 · Cited by 80
McNamara, K. M., Yoda, T., Miki, Y., Chanplakorn, N., Wongwaisayawan, S., Incharoen, P., Kongdan, Y., Wang, L., Takagi, K., Takagi, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12121 · Cited by 79
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
Narayanan, R., & Dalton, J. T. (2016) · Cancers · doi:10.3390/cancers8120108 · Cited by 69
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
Caiazza, F., Murray, A. M., Madden, S. F., Synnott, N. C., Ryan, E. J., O’Donovan, N., Crown, J. P., & Duffy, M. J. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0068 · Cited by 63
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
Cuenca-López, M. D., Montero, J. C., Morales, J. C., Prat, A., Pandiella, A., & Ocaña, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-302 · Cited by 61
Wang, Y., He, X., Yu, Q., & Eng, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt077 · Cited by 57
Hilborn, E., Gacic, J., Fornander, T., Nordenskjöld, B. A., Stål, O., & Jansson, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.464 · Cited by 53
Triple negative breast cancer: Deciphering the biology and heterogeneity
Uscanga‐Perales, G., Santuario-Facio, S. K., & Ortı́z-López, R. (2016) · Medicina Universitaria · doi:10.1016/j.rmu.2016.05.007 · Cited by 45
Robles, A. J., Cai, S., Cichewicz, R. H., & Mooberry, S. L. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3841-9 · Cited by 44
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
Luo, J., Jin, J., Yang, F., Sun, Z., Zhang, W., Shi, Y., Xu, J., & Guan, X. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16176 · Cited by 36
von Wahlde, M., Hülsewig, C., Ruckert, C., Götte, M., Kiesel, L., & Bernemann, C. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.971235 · Cited by 25
Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer.
Nakano, K., Miki, Y., Hata, S., Ebata, A., Takagi, K., McNamara, K. M., Sakurai, M., Masuda, M., Hirakawa, H., Ishida, T., et al. (2013) · PubMed · Cited by 21
McNamara, K. M., & Sasano, H. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000251 · Cited by 17
Carles, J., Gallardo, E., Domènech, M., Pous, A. F., Joaquim Bellmunt, B., Mellado, B., Suárez, C., Bonfill, T., Sáez, M. I., Guix, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.7_suppl.15 · Cited by 17
Cited by
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Pathology of triple negative breast cancer
Borri, F., & Granaglia, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.005 · Cited by 300
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Metadata
- Authors
- Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., Del Mastro, L., De Laurentiis, M., Puglisi, F., & Arpino, G.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 68
- Pages
- 102-110
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2807966236
- Cited by
- 285
- References
- 56
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.